Chiron IntraOptics Inc. said Monday that it has signedagreements to develop and market a drug implant system forintraocular delivery of therapeutic products, and an excimerlaser for refractive surgery.
Chiron IntraOptics, a business unit of Chiron Corp.(NASDAQ:CHIR) of Emeryville, Calif., said it licensed exclusiveworldwide rights for ophthalmic applications of drug deliverytechnology from Control Delivery Systems Inc. (CDS). ChironIntraOptics has also purchased 30 percent of the equity of CDS.
Chiron IntraOptics said it will sponsor clinical trials currentlyunder way studying the delivery system's effectiveness indelivering anti-virals into the eye for treating retinitis causedby cytomegalovirus, a late-stage infection that leads toblindness in AIDS patients. Phase III trials are planned forearly this year.
With the CDS system, the company said, anti-virals can beimplanted into the vitreous of the eye to deliver a sustaineddose for four to eight months.
Chiron IntraOptics said it has purchased U.S. ophthalmicmarketing rights for excimer lasers for refractive surgeryproduced by Tehnolas GmbH of Munich, Germany, and said itplans to acquire exclusive worldwide ophthalmic distributionrights for these products.
(c) 1997 American Health Consultants. All rights reserved.